How do I implement pathogen-reduced platelets?

Area of Science:

• Blood banking and transfusion medicine
• Microbiology and infectious diseases
• Regulatory affairs in healthcare

Background:

• Bacterial contamination of platelet products is an ongoing safety concern despite risk mitigation.
• A 2018 Food and Drug Administration (FDA) guidance provides pathways for reducing bacterial risk in platelets.
• Compliance requires collaboration between hospital blood banks and donor centers to assess various factors.

Purpose of the Study:

• To evaluate the implementation of pathogen reduction technology for platelet safety.
• To assess the impact of this transition on platelet collection, processing, and inventory management.
• To provide a roadmap for institutions considering FDA-compliant methods for bacterial risk reduction.

Main Methods:

• Institutions assessed factors including platelet shelf-life, bacterial testing, low-yield platelet efficacy, and inventory management.
• Trials were conducted with varied collection settings, target volumes, and platelet yields to optimize production.
• Hospitals reviewed low-yield platelet products and their clinical efficacy, necessitating interdisciplinary collaboration and training.

Main Results:

• The transition to pathogen-reduced platelets presented challenges with over-concentrated products or low platelet yields.
• Optimized production settings were identified through trials at the blood donor center.
• Successful implementation required hospital-level review of low-yield products and clinical efficacy, alongside comprehensive staff education.

Conclusions:

• Pathogen-reduced platelets are identified as the most efficient method for institutional compliance with FDA guidance.
• The study offers a roadmap for institutions navigating FDA-prescribed methods for bacterial risk reduction.
• Optimization of collections to effectively utilize low-yield products is crucial for institutions adopting pathogen reduction technology.